Pfizer Sees No Future In NicOx Glaucoma Candidate After Failure In Japanese Phase II Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Collaboration turns to diabetic retinopathy after Pfizer backs away from PF-03187207 development.